Rani Therapeutics Holdings, Inc.

NasdaqGM:RANI Stock Report

Market Cap: US$80.4m

Rani Therapeutics Holdings Management

Management criteria checks 2/4

Rani Therapeutics Holdings' CEO is Talat Imran, appointed in Jun 2021, has a tenure of 3.5 years. total yearly compensation is $5.27M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 0.65% of the company’s shares, worth $526.57K. The average tenure of the management team and the board of directors is 3.5 years and 3.7 years respectively.

Key information

Talat Imran

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage8.5%
CEO tenure3.5yrs
CEO ownership0.7%
Management average tenure3.5yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Jul 16
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Mar 20
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development

Aug 08

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Feb 13
We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

CEO Compensation Analysis

How has Talat Imran's remuneration changed compared to Rani Therapeutics Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$31m

Mar 31 2024n/an/a

-US$33m

Dec 31 2023US$5mUS$450k

-US$34m

Sep 30 2023n/an/a

-US$36m

Jun 30 2023n/an/a

-US$34m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$4mUS$515k

-US$31m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$12mUS$408k

-US$8m

Compensation vs Market: Talat's total compensation ($USD5.27M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Talat's compensation has increased whilst the company is unprofitable.


CEO

Talat Imran (42 yo)

3.5yrs

Tenure

US$5,266,893

Compensation

Mr. Talat Imran serves as an Investment Professional at VHM Ventures. He has served as Chief Executive Officer and Director of Rani Therapeutics Holdings, Inc. since June 2021 and served as its Vice Presid...


Leadership Team

NamePositionTenureCompensationOwnership
Mir Imran
Executive Chairmanno dataUS$398.55k0.064%
$ 51.6k
Talat Imran
CEO & Director3.5yrsUS$5.27m0.65%
$ 526.6k
Svai Sanford
Chief Financial Officer6.1yrsUS$2.16m0.42%
$ 341.5k
Mir Hashim
Chief Scientific Officer11.5yrsUS$2.17m0.45%
$ 358.2k
Alireza Javadi
Vice President of Technical Operationsless than a yearno datano data
Eric Groen
General Counsel3.4yrsno data0.018%
$ 14.1k
Bella Vazquez
Vice President of Human Resources3.9yrsno datano data
Kate McKinley
Chief Business Officer1.6yrsno data0.054%
$ 43.4k
Arvinder Dhalla
Vice President of Clinical Developmentno datano datano data

3.5yrs

Average Tenure

53.5yo

Average Age

Experienced Management: RANI's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mir Imran
Executive Chairmanno dataUS$398.55k0.064%
$ 51.6k
Talat Imran
CEO & Director3.5yrsUS$5.27m0.65%
$ 526.6k
Laureen DeBuono
Lead Independent Director3.7yrsUS$436.47k0.84%
$ 672.4k
Jean-Luc Butel
Independent Director3.7yrsUS$393.97k0.84%
$ 672.4k
Dennis Ausiello
Independent Director6.3yrsUS$378.10k0.66%
$ 530.5k
Andrew Farquharson
Director12.5yrsUS$363.55k0%
$ 0
Maulik Nanavaty
Independent Director8.5yrsUS$396.60k0.033%
$ 26.6k
Lisa Rometty
Independent Director2.9yrsUS$388.62k0.47%
$ 375.4k

3.7yrs

Average Tenure

64yo

Average Age

Experienced Board: RANI's board of directors are considered experienced (3.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rani Therapeutics Holdings, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Julian HarrisonBTIG
Edward NashCanaccord Genuity